Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 2Thoracic 1Plasma cell 1Other solid neoplasm 1Genitourinary 1

Conditions

Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 109pembrolizumab 93Pemetrexed 83Cisplatin 67Specimen Handling 41durvalumab 36Paclitaxel 36Nivolumab 33Docetaxel 33atezolizumab 30Magnetic Resonance Spectroscopy 30osimertinib 29Radiotherapy 21Gemcitabine 21Etoposide 21130-nm albumin-bound paclitaxel 19Cetuximab 17amivantamab 14Radiosurgery 13Radiation 12Platinum 12Bevacizumab 12lazertinib 11cemiplimab 11Taxes 11Immunoglobulin G 11Topotecan 10Ipilimumab 10Drug Therapy 10Disulfides 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
pegylated granulocyte colony-stimulating factor × Thoracic × 30 days × Clear all
NCT00334815 2026-05-26

Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Active not recruiting
29 enrolled 10 charts
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar

Data powered by HemOnc (CC BY 4.0) Colophon âš¡